Abstract
Prostate cancer is the most prevalent cancer in men, with relevant social and economic impacts. The phenotype and course of the disease span a broad spectrum, from an indolent tumor to an aggressive metastatic carcinoma. Current clinicopathological markers are insufficient to capture this spectrum of patients, especially those at risk of treatment failure and with poor prognosis. Even wit…